NCT07345052 Western Sweden Systemic Sclerosis Project
| NCT ID | NCT07345052 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sahlgrenska University Hospital |
| Condition | Scleroderma, Systemic |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2022-06-20 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2022-06-20 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main aim of the project is to identify key-factors involved in the development and progression of Systemic Sclerosis (SSc), a chronic invalidating rheumatic disease characterized by high mortality and insufficient treatment options. A cohort of patients with SSc will be collected at the Sahlgrenska University Hospital in Gothenburg, Skaraborg Hospital in Skövde, and Södra Älvsborg Hospital in Borås (Sweden). Thanks to a holistic approach including integrated analysis of blood, and skin samples as well as DNA, and with the use of state-of-the-art methods, this project aims to identify factors (e.g. genes, proteins, metabolites, and immune cell types) associated with the development of SSc and with the progression to a more aggressive phenotype. Functional studies using in vitro model systems and patient specimens will be also implemented. The findings of the current project could lead to the identification of possible diagnostic and prognostic markers for the disease as well as potential drug targets. This cohort will be also linked to the European Scleroderma Trial and Research (EUSTAR), which is an international SSc research network aiming to coordinate research activities on SSc from groups all over Europe in order to improve treatment, quality of life and mortality of patients with SSc.
Eligibility Criteria
Inclusion Criteria: * Participants diagnosed with SSc according to the ACR and EULAR classification criteria Exclusion Criteria: * Diagnosis of Mixed connective tissue disease * Not speaking or reading Swedish * With severe cognitive impairment * With blood count below specified limits * Allergy to local anaesthetic (for subjects who will provide a skin biopsy)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07345052 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Scleroderma, Systemic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07345052 currently recruiting?
Yes, NCT07345052 is actively recruiting participants. Contact the research team at cristina.maglio@gu.se for enrollment information.
Where is the NCT07345052 trial being conducted?
This trial is being conducted at Gothenburg, Sweden.
Who is sponsoring the NCT07345052 clinical trial?
NCT07345052 is sponsored by Sahlgrenska University Hospital. The trial plans to enroll 150 participants.